Cargando…

Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease

INTRODUCTION: Progression of fibrosis in interstitial lung diseases (ILD) has been associated with poor prognosis, lower quality of life for patients and caregivers, and higher healthcare costs. This study estimated the burden of disease and productivity loss of progressively fibrosing ILD, focusing...

Descripción completa

Detalles Bibliográficos
Autores principales: Løkke, Anders, Castello, Luca, Pinheiro Martins, Pedro, Soulard, Stéphane, Hilberg, Ole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611590/
https://www.ncbi.nlm.nih.gov/pubmed/37837527
http://dx.doi.org/10.1007/s12325-023-02701-z
_version_ 1785128523293261824
author Løkke, Anders
Castello, Luca
Pinheiro Martins, Pedro
Soulard, Stéphane
Hilberg, Ole
author_facet Løkke, Anders
Castello, Luca
Pinheiro Martins, Pedro
Soulard, Stéphane
Hilberg, Ole
author_sort Løkke, Anders
collection PubMed
description INTRODUCTION: Progression of fibrosis in interstitial lung diseases (ILD) has been associated with poor prognosis, lower quality of life for patients and caregivers, and higher healthcare costs. This study estimated the burden of disease and productivity loss of progressively fibrosing ILD, focusing on progressive pulmonary fibrosis other than idiopathic pulmonary fibrosis (non-IPF PPF) and systemic sclerosis-associated ILD (SSc-ILD) in the European Economic Area (EEA). METHODS: An economic model was built to estimate the clinical burden of SSc-ILD and non-IPF PPF. The model was based on published data on disease prevalence and disease burden (in terms of comorbidities, exacerbations, and deaths) as well as on productivity loss (in terms of sick days, early retirement, permanent disability, and job loss). Aggregate income loss was obtained by multiplying productivity loss by the median daily income in each country/area of investigation. A sensitivity analysis was performed to test the impact of the variability of the model assumptions. RESULTS: In the whole EEA, a total of 86,794 and 13,221 individuals were estimated to be affected by non-IPF PPF and SSc-ILD, respectively. Estimated annual sick days associated with the diseases were 3,952,604 and 672,172, early retirements were 23,174 and 5341, permanently disabled patients were 41,748 and 4037, and job losses were 19,789 and 2617 for non-IPF PPF and SSc-ILD, respectively. Annual exacerbations were estimated to be 22,401–31,181 and 1259–1753, while deaths were 5791–6171 and 572–638 in non-IPF PPF and SSc-ILD, respectively. The estimated annual aggregate income loss in EEA, accounting for losses due to annual sick days, early retirements, and permanently disabled patients, was €1433 million and €220 million in non-IPF PPF and SSc-ILD, respectively. The productivity loss due to job losses was €194 million and €26 million in non-IPF PPF and SSc-ILD, respectively. The main driver of aggregate income loss variability was the prevalence. CONCLUSION: The impact of non-IPF PPF and SSc-ILD on society is definitely non-negligible. Actions to reduce the burden on our societies are highly needed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-023-02701-z.
format Online
Article
Text
id pubmed-10611590
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-106115902023-10-29 Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease Løkke, Anders Castello, Luca Pinheiro Martins, Pedro Soulard, Stéphane Hilberg, Ole Adv Ther Original Research INTRODUCTION: Progression of fibrosis in interstitial lung diseases (ILD) has been associated with poor prognosis, lower quality of life for patients and caregivers, and higher healthcare costs. This study estimated the burden of disease and productivity loss of progressively fibrosing ILD, focusing on progressive pulmonary fibrosis other than idiopathic pulmonary fibrosis (non-IPF PPF) and systemic sclerosis-associated ILD (SSc-ILD) in the European Economic Area (EEA). METHODS: An economic model was built to estimate the clinical burden of SSc-ILD and non-IPF PPF. The model was based on published data on disease prevalence and disease burden (in terms of comorbidities, exacerbations, and deaths) as well as on productivity loss (in terms of sick days, early retirement, permanent disability, and job loss). Aggregate income loss was obtained by multiplying productivity loss by the median daily income in each country/area of investigation. A sensitivity analysis was performed to test the impact of the variability of the model assumptions. RESULTS: In the whole EEA, a total of 86,794 and 13,221 individuals were estimated to be affected by non-IPF PPF and SSc-ILD, respectively. Estimated annual sick days associated with the diseases were 3,952,604 and 672,172, early retirements were 23,174 and 5341, permanently disabled patients were 41,748 and 4037, and job losses were 19,789 and 2617 for non-IPF PPF and SSc-ILD, respectively. Annual exacerbations were estimated to be 22,401–31,181 and 1259–1753, while deaths were 5791–6171 and 572–638 in non-IPF PPF and SSc-ILD, respectively. The estimated annual aggregate income loss in EEA, accounting for losses due to annual sick days, early retirements, and permanently disabled patients, was €1433 million and €220 million in non-IPF PPF and SSc-ILD, respectively. The productivity loss due to job losses was €194 million and €26 million in non-IPF PPF and SSc-ILD, respectively. The main driver of aggregate income loss variability was the prevalence. CONCLUSION: The impact of non-IPF PPF and SSc-ILD on society is definitely non-negligible. Actions to reduce the burden on our societies are highly needed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-023-02701-z. Springer Healthcare 2023-10-14 2023 /pmc/articles/PMC10611590/ /pubmed/37837527 http://dx.doi.org/10.1007/s12325-023-02701-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Løkke, Anders
Castello, Luca
Pinheiro Martins, Pedro
Soulard, Stéphane
Hilberg, Ole
Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease
title Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease
title_full Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease
title_fullStr Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease
title_full_unstemmed Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease
title_short Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease
title_sort burden of disease and productivity loss in the european economic area in patients affected by fibrosing interstitial lung disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611590/
https://www.ncbi.nlm.nih.gov/pubmed/37837527
http://dx.doi.org/10.1007/s12325-023-02701-z
work_keys_str_mv AT løkkeanders burdenofdiseaseandproductivitylossintheeuropeaneconomicareainpatientsaffectedbyfibrosinginterstitiallungdisease
AT castelloluca burdenofdiseaseandproductivitylossintheeuropeaneconomicareainpatientsaffectedbyfibrosinginterstitiallungdisease
AT pinheiromartinspedro burdenofdiseaseandproductivitylossintheeuropeaneconomicareainpatientsaffectedbyfibrosinginterstitiallungdisease
AT soulardstephane burdenofdiseaseandproductivitylossintheeuropeaneconomicareainpatientsaffectedbyfibrosinginterstitiallungdisease
AT hilbergole burdenofdiseaseandproductivitylossintheeuropeaneconomicareainpatientsaffectedbyfibrosinginterstitiallungdisease